Honeysuckle-Derived Exosome-Like Nanovesicles Protect Against Acute Liver Failure by Modulating Gut Microbiota

Area of Science:

• Nanomedicine
• Hepatology
• Natural Product Therapeutics

Background:

• Acute liver failure (ALF) is a critical condition with limited treatment options, often necessitating liver transplantation.
• Current therapies are mostly single-target and lack cost-effectiveness.
• There is a pressing need for novel, multi-target therapeutic strategies for ALF.

Purpose of the Study:

• To investigate the therapeutic potential of honeysuckle nanovesicles (HNVs) in an experimental model of acute liver failure.
• To characterize HNVs and assess their safety and distribution in vivo.
• To elucidate the underlying mechanisms of HNVs in mitigating ALF.

Main Methods:

• Isolation and characterization of HNVs using Cryo-EM, TEM, and DLS.
• Assessment of HNV stability in simulated gastrointestinal fluid.
• Evaluation of HNVs' therapeutic efficacy in a lipopolysaccharide/D-galactosamine (LPS/GalN)-induced ALF mouse model.
• Mechanism elucidation using RNA sequencing, 16S rRNA analysis, Western blot, and qPCR.

Main Results:

• HNVs significantly reduced serum ALT and AST levels in ALF mice.
• HNVs ameliorated hepatocellular necrosis and inflammatory infiltration.
• HNVs demonstrated dual-targeting action by traversing the intestinal barrier to suppress liver inflammation and restoring gut integrity to reduce LPS translocation.

Conclusions:

• Honeysuckle nanovesicles (HNVs) represent a novel natural nanomedicine with dual-targeting capabilities for ALF.
• HNVs offer a promising and potentially cost-effective therapeutic alternative for acute liver failure.
• This study highlights the potential of natural product-derived nanomedicines in treating complex liver diseases.